Table 15:
Mortality Outcomes in Single-Site European Trials of PSA Screening for Prostate Cancer
| Norrkoping (44;51) 15-Year Follow-Up | Stockholm (43) 12.9-Year Follow-Up | Goteborg (53) 14-Year Follow-Up | ||||
|---|---|---|---|---|---|---|
| Screen Group | Control Group | Screen Group | Control Group | Screen Group | Control Group | |
| Participants, n | 1,494 | 7,532 | 2,374 | 24,772 | 9,952 | 9,952 |
| PC cases, n (%) | 85 (5.7) | 292 (3.9) | 208 (8.7) | 1,972 (8.1) | 1,138 (11.4) | 718 (7.2) |
| PC/1,000 men | 57 | 39 | 88 | 80 | 114 | 72 |
| PC/1,000 P-YR (95% CI) | NR | NR | 4.0 (3.4–4.7) | 5.2 (5.0–5.4) | NR | NR |
| PC deaths, n | 20 | 97 | 53 | 506 | 44 | 78 |
| Deaths/1,000 P-YR (95% CI) | NR | NR | 1.72 (1.32–2.26) | 1.57 (1.44–1.71) | NR | NR |
| RR (95% CI) | 1.16 (0.78–1.73) | 1.10 (0.83–1.46) | 0.56 (0.39–0.82) | |||
| ARD | 0.15/1,000 P-YR | 0.40% (95% CI, 0.17–0.64) | ||||
| Total deaths, n | NR | NR | 933 | 9,822 | 1,981 | 1,982 |
| Deaths/1,000 P-YR (95% CI) | NR | NR | 30.4 (28.5–32.4) | 30.5 (29.9–31.1) | NR | NR |
| RR (95% CI) | NR | 0.98 (0.92–1.05) | NR | |||
| ARD | NR | 0.1 / 1,000 P-YR | NR | |||
Abbreviations: ARD, absolute risk difference; CI, confidence interval; n, number; NR, not reported; PC, prostate cancer; P-YR, person year; RR, relative risk.